{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:23:07Z","timestamp":1792959787289,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.rmed.2026.108741","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:56:23Z","timestamp":1772207783000},"page":"108741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effect of vanzacaftor\/tezacaftor\/ivacaftor on cystic fibrosis nasal epithelial cells and intestinal organoids compared to elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-1302","authenticated-orcid":false,"given":"Lucie","family":"Borek-Dohalska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-7797","authenticated-orcid":false,"given":"Martin","family":"Modrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4187-722X","authenticated-orcid":false,"given":"Stepanka","family":"Novotna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6318-6645","authenticated-orcid":false,"given":"Eva","family":"Furstova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Varenyiova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Dousova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Drevinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.rmed.2026.108741_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"4922","key":"10.1016\/j.rmed.2026.108741_bib2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.rmed.2026.108741_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biocel.2014.03.020","article-title":"Biosynthesis of cystic fibrosis transmembrane conductance regulator","volume":"52","author":"Pranke","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"2","key":"10.1016\/j.rmed.2026.108741_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.chest.2018.04.036","article-title":"Ion channel modulators in cystic fibrosis","volume":"154","author":"Gentzsch","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2026.108741_bib5","article-title":"Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy","volume":"vol. 17","author":"Tewkesbury","year":"2021"},{"key":"10.1016\/j.rmed.2026.108741_bib6","first-page":"381","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021"},{"issue":"6","key":"10.1016\/j.rmed.2026.108741_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"10212","key":"10.1016\/j.rmed.2026.108741_bib8","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.rmed.2026.108741_bib9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2026.108741_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor\u2013tezacaftor\u2013deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2026.108741_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor for children aged 6\u201311 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2026.108741_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108741_bib15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2024.12.006","article-title":"Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment","volume":"24","author":"Zemanick","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2026.108741_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101419","article-title":"Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants","volume":"3","author":"Golec","year":"2022","journal-title":"STAR Protoc."},{"issue":"4","key":"10.1016\/j.rmed.2026.108741_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2026.108741_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcf.2021.07.006","article-title":"Response to elexacaftor\/tezacaftor\/ivacaftor in intestinal organoids derived from people with cystic fibrosis","volume":"21","author":"Furstova","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2026.108741_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00156-2024","article-title":"Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay","volume":"63","author":"Furstova","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"344","key":"10.1016\/j.rmed.2026.108741_bib20","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"7244","key":"10.1016\/j.rmed.2026.108741_bib21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.rmed.2026.108741_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-9-482","article-title":"CellProfiler Analyst: data exploration and analysis software for complex image-based screens","volume":"9","author":"Jones","year":"2008","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.rmed.2026.108741_bib23","author":"Bates"},{"key":"10.1016\/j.rmed.2026.108741_bib24","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing [Internet]","volume":"57","author":"Benjaminit","year":"1995","journal-title":"J. Roy. Stat. Soc. B."},{"key":"10.1016\/j.rmed.2026.108741_bib25","series-title":"R: a Language and Environment for Statistical Computing","year":"2024"},{"issue":"16","key":"10.1016\/j.rmed.2026.108741_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176328","article-title":"Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121","volume":"134","author":"Kolski-Andreaco","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.rmed.2026.108741_bib27","article-title":"(R)-vanzacaftor potentiates BKCa channels in the absence of CFTR correction or potentiation","volume":"8","author":"Kolski-Andreaco","year":"2025","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"5","key":"10.1016\/j.rmed.2026.108741_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"19","key":"10.1016\/j.rmed.2026.108741_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914539","article-title":"CFTR function restoration upon Elexacaftor\/Tezacaftor\/Ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.rmed.2026.108741_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcf.2024.09.019","article-title":"Elexacaftor\/tezacaftor\/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls","author":"Kroes","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.rmed.2026.108741_bib31","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jcf.2025.02.008","article-title":"Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers","volume":"24","author":"Conti","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108741_bib32","article-title":"Personalized medicine in cystic fibrosis: characterization of eight rare CFTR variants in intestinal organoids and cellular models","volume":"13","author":"Railean","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.rmed.2026.108741_bib33","doi-asserted-by":"crossref","unstructured":"Amaral MD, Pankonien I. Theranostics vs theratyping or theranostics plus theratyping? J. Cyst. Fibros. Jan;24(1):10-15. doi: 10.1016\/j.jcf.2024.09.013.36.","DOI":"10.1016\/j.jcf.2024.09.013"},{"issue":"4","key":"10.1016\/j.rmed.2026.108741_bib34","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jcf.2019.10.022","article-title":"Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations","volume":"19","author":"de Winter \u2013 de Groot","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.rmed.2026.108741_bib35","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201857","article-title":"Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis","volume":"6","author":"Birimberg-Schwartz","year":"2023","journal-title":"Life Sci. Alliance"},{"issue":"5","key":"10.1016\/j.rmed.2026.108741_bib36","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jcf.2025.08.011","article-title":"Correlation between patient-derived intestinal organoids and clinical responses to CFTR modulators in people with cystic fibrosis homozygous for F508del","volume":"24","author":"Rodriguez Mier","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.rmed.2026.108741_bib37","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01855-2024","article-title":"Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis","volume":"65","author":"Ratjen","year":"2025","journal-title":"Eur. Respir. J."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:29:07Z","timestamp":1777595347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126001095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"alternative-id":["S0954611126001095"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108741","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of vanzacaftor\/tezacaftor\/ivacaftor on cystic fibrosis nasal epithelial cells and intestinal organoids compared to elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108741"}}